Basic Information
| LncRNA/CircRNA Name | SLC16A1-AS1 |
| Synonyms | NA |
| Region | GRCh38_1:112956415-113047055 |
| Ensemble | ENSG00000226419 |
| Refseq | NR_103743 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | non small cell lung cancer |
| ICD-0-3 | C34 |
| Methods | Microarray, qPCR, vWestern blot |
| Sample | NSCLC cell lines (A549 and NCI-H460) and human lung epithelial cells (BEAS-2B)., Lung cancer tissue and adjacent normal tissue |
| Expression Pattern | down-regulated |
| Function Description | It was showed that SLC16A1-AS1 was remarkably downregulated in NSCLC tissues and cell lines. Functionally, SLC16A1-AS1 overexpression could inhibit the viability and proliferation of lung cancer cell, block the cell cycle and promote cell apoptosis in vitro which may result from reduced phosphorylation of rat sarcoma (RAS)/ proto-oncogene serine/ threonine-protein kinase (RAF)/ mitogen-activated protein kinase kinase (MEK)/ extracellular regulated protein kinases (ERK) pathway caused by elevated expression of SLC16A1-AS1. Clinical sample analysis showed that SLC16A1-AS1 had a favorable impact on the overall survival and progression-free survival of patients with NSCLC. |
| Pubmed ID | 31371390 |
| Year | 2019 |
| Title | lncRNA SLC16A1-AS1 as a novel prognostic biomarker in non-small cell lung cancer |
External Links
| Links for SLC16A1-AS1 | GenBank HGNC NONCODE |
| Links for non small cell lung cancer | OMIM COSMIC |